Cargando…
Identification of CDK1, PBK, and CHEK1 as an Oncogenic Signature in Glioblastoma: A Bioinformatics Approach to Repurpose Dapagliflozin as a Therapeutic Agent
Glioblastoma multiforme (GBM) is the most aggressive and lethal primary brain tumor whose median survival is less than 15 months. The current treatment regimen comprising surgical resectioning, chemotherapy with Temozolomide (TMZ), and adjuvant radiotherapy does not achieve total patient cure. Stem...
Autores principales: | Chinyama, Harold A., Wei, Li, Mokgautsi, Ntlotlang, Lawal, Bashir, Wu, Alexander T. H., Huang, Hsu-Shan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10671581/ https://www.ncbi.nlm.nih.gov/pubmed/38003585 http://dx.doi.org/10.3390/ijms242216396 |
Ejemplares similares
-
Network Pharmacological Analysis through a Bioinformatics Approach of Novel NSC765600 and NSC765691 Compounds as Potential Inhibitors of CCND1/CDK4/PLK1/CD44 in Cancer Types
por: Mokgautsi, Ntlotlang, et al.
Publicado: (2021) -
A Preclinical Investigation of GBM-N019 as a Potential Inhibitor of Glioblastoma via Exosomal mTOR/CDK6/STAT3 Signaling
por: Wu, Alexander T. H., et al.
Publicado: (2021) -
An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential GSK3β/β-Catenin/STAT3/CD44 Suppressor with Anti-Glioblastoma Properties
por: Mokgautsi, Ntlotlang, et al.
Publicado: (2021) -
Pharmacoinformatics and Preclinical Studies of NSC765690 and NSC765599, Potential STAT3/CDK2/4/6 Inhibitors with Antitumor Activities against NCI60 Human Tumor Cell Lines
por: Lawal, Bashir, et al.
Publicado: (2021) -
In-Silico Evaluation of Genetic Alterations in Ovarian Carcinoma and Therapeutic Efficacy of NSC777201, as a Novel Multi-Target Agent for TTK, NEK2, and CDK1
por: Khedkar, Harshita Nivrutti, et al.
Publicado: (2021)